What are the current guideline recommendations for the diagnosis and management of mitral stenosis?

Recent Guidelines in Mitral Stenosis

Diagnostic Approach

Transthoracic echocardiography (TTE) is the preferred initial diagnostic technique for both diagnosis and severity assessment of mitral stenosis. 1

Echocardiographic Criteria for Severe Mitral Stenosis

• Mitral valve area (MVA) ≤1.5 cm² by planimetry or pressure half-time method defines severe mitral stenosis 2
• Mean transmitral gradient >5-10 mmHg at normal heart rate 2
• Diastolic pressure half-time ≥150 ms 2
• Pulmonary artery systolic pressure >30 mmHg 2

Important caveat: Planimetry at the leaflet tips is the reference method but requires experienced operators; pressure half-time should be used cautiously in elderly patients or those with atrial fibrillation as it may overestimate severity 1, 3

Additional Imaging

• Transesophageal echocardiography (TOE) is indicated to exclude left atrial thrombus before percutaneous mitral balloon commissurotomy (PMBC), evaluate concurrent mitral regurgitation severity, and clarify valve anatomy when TTE is limited 1
• 3D echocardiography produces greater accuracy of MVA measurement 1
• Exercise stress echocardiography is reasonable when discrepancy exists between symptoms and resting severity 1

Medical Management

Medical therapy is purely palliative and does not prevent disease progression; it serves only to relieve symptoms while monitoring for intervention indications. 4

Heart Rate Control

• Beta-blockers or rate-limiting calcium channel blockers are recommended for heart rate control, particularly crucial in atrial fibrillation to prolong diastolic filling time 2, 5, 4
• Digoxin specifically for heart rate control in atrial fibrillation 2, 5, 4

Volume Management

• Diuretics for symptom relief when pulmonary congestion or peripheral edema is present 2, 5, 4

Anticoagulation

Vitamin K antagonists (target INR 2-3) are mandatory—NOT direct oral anticoagulants—in the following situations: 2, 5, 4

• Atrial fibrillation (most common indication)
• History of systemic embolism
• Dense spontaneous contrast in left atrium on echocardiography
• Enlarged left atrium (diameter >60 mL/m²)

Critical pitfall: NOACs are contraindicated in mitral stenosis patients with atrial fibrillation; only vitamin K antagonists should be used 4

Intervention Indications

Symptomatic Patients

All symptomatic patients (NYHA class II-IV) with severe mitral stenosis (MVA ≤1.5 cm²) require intervention. 1, 2, 5

Asymptomatic Patients

Intervention is indicated in asymptomatic severe mitral stenosis when ANY of the following are present: 1, 2, 5

• Pulmonary artery systolic pressure >50 mmHg
• New-onset atrial fibrillation
• High thromboembolic risk (history of embolism or dense spontaneous contrast)

Intervention Selection

Percutaneous mitral balloon commissurotomy (PMBC) is the first-line intervention for all patients with favorable valve morphology. 1, 2, 5, 3, 6

Favorable Anatomy for PMBC

• Wilkins echocardiographic score ≤8 1
• Minimal valve calcification 2
• No significant mitral regurgitation (grade <2/4) 3
• Commissural fusion present (characteristic of rheumatic etiology) 5

Unfavorable Characteristics Requiring Surgery

Mitral valve surgery (open commissurotomy or valve replacement) is indicated when: 1

• Wilkins score >8
• Heavy valve calcification
• Severe subvalvular fusion
• Moderate-to-severe mitral regurgitation (≥2/4)
• Degenerative mitral stenosis (lacks commissural fusion, making PMBC ineffective) 1, 5

Critical distinction: Rheumatic MS has commissural fusion amenable to PMBC; degenerative MS lacks this and requires surgery 5

Special Populations

Pregnancy

A multidisciplinary team involving cardiologists, obstetricians, and anesthesiologists must manage all pregnant women with mitral stenosis. 1

• PMBC should be performed before pregnancy in women with moderate-to-severe MS who are considering pregnancy 1
• During pregnancy, PMBC can be performed relatively safely in symptomatic patients (NYHA III-IV) despite medical therapy 1, 5
• Mitral valve surgery during pregnancy carries significant risk to mother and fetus; reserved only when mother's life is threatened 1, 5
• Beta-blockers for heart rate control during pregnancy (beta-1 selective preferred) 1

Non-Cardiac Surgery

Patients with MVA >1.5 cm² and asymptomatic status with pulmonary artery systolic pressure <50 mmHg can safely undergo elective non-cardiac surgery. 1

• In symptomatic patients or those with PASP >50 mmHg, correct MS with PMBC before high-risk non-cardiac surgery whenever possible 1

Monitoring and Follow-Up

Asymptomatic Severe Mitral Stenosis

• Echocardiographic assessment every 2-3 years (ESC recommendation) 2, 4
• ACC/AHA recommends every 3-5 years 4
• More frequent monitoring (yearly) for very severe stenosis or borderline hemodynamics 2

Post-Intervention

Monitor for: 5

• Mitral valve area achieved
• Residual mitral regurgitation severity
• Mean transmitral gradient
• Pulmonary artery pressure

Clinical Surveillance

Regular evaluation for development of: 2

• New symptoms
• Atrial fibrillation
• Pulmonary hypertension

Key Pitfalls to Avoid

• Never use NOACs in mitral stenosis patients with atrial fibrillation—only vitamin K antagonists 4
• Do not rely solely on pressure half-time in elderly patients or atrial fibrillation; it overestimates severity 1, 3
• Recognize that low-gradient severe MS (mean gradient <10 mmHg) may have less symptomatic benefit from intervention, particularly with low flow 7
• Medical therapy alone does not prevent progression; regular monitoring for intervention indications is essential 4
• Distinguish rheumatic from degenerative MS before planning intervention—PMBC is ineffective in degenerative MS 1, 5